Literature DB >> 17999635

Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2.

Dianne M Walters1, Hye-Youn Cho, Steven R Kleeberger.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disorder in which excessive deposition of extracellular matrix leads to irreversible scarring of interstitial lung tissue. The etiology of IPF remains unknown, but growing evidence suggests that disequilibrium in oxidant/antioxidant balance contributes significantly. IPF is currently regarded as a fibroproliferative disorder triggered by repeated alveolar epithelial cell injury. Oxidative stress plays a role in many processes involved in alveolar epithelial cell injury and fibrogenesis. Here we review the role of oxidative stress in IPF, and other forms of pulmonary fibrosis, with particular attention to antioxidant defenses regulated by the redox-sensitive transcription factor nuclear factor, erythroid derived 2, like (Nrf2). Nrf2 binds specific antioxidant response elements (AREs) in the promoter of antioxidant enzyme and defense protein genes and regulates their expression in many tissue types. Nrf2 protects from several phenotypes in which enhanced oxidative burden contributes to disease pathogenesis, including cancer, acute lung injury, and pulmonary fibrosis. We suggest that promoter polymorphisms in human NRF2 may contribute to IPF susceptibility, although this hypothesis has not been tested. Pulmonary fibrosis is a highly complex disease and involves multiple genes and processes, and new therapies for cellular and molecular targets involved in pathogenic mechanisms are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17999635     DOI: 10.1089/ars.2007.1901

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  64 in total

1.  Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system.

Authors:  Yin Liu; Wei Gao; Deping Zhang
Journal:  Clin Exp Med       Date:  2009-11-19       Impact factor: 3.984

2.  Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains.

Authors:  Toshihiko Ogura; Kit I Tong; Kazuhiro Mio; Yuusuke Maruyama; Hirofumi Kurokawa; Chikara Sato; Masayuki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

3.  NRF2 deficiency reduces life span of mice administered thoracic irradiation.

Authors:  Elizabeth L Travis; Girish Rachakonda; Xinhui Zhou; Katrina Korhonen; Konjeti R Sekhar; Swati Biswas; Michael L Freeman
Journal:  Free Radic Biol Med       Date:  2011-06-12       Impact factor: 7.376

4.  Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.

Authors:  Tomonaga Ichikawa; Jinqing Li; Colin J Meyer; Joseph S Janicki; Mark Hannink; Taixing Cui
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

5.  Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice.

Authors:  Pooja Shivshankar; Christopher Brampton; Shelley Miyasato; Michael Kasper; Victor J Thannickal; Claude Jourdan Le Saux
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-23       Impact factor: 6.914

6.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

7.  Inhibitory Effects of Astragaloside IV on Bleomycin-Induced Pulmonary Fibrosis in Rats Via Attenuation of Oxidative Stress and Inflammation.

Authors:  Wei-Na Yu; Li-Feng Sun; Hua Yang
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

8.  Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways.

Authors:  Haiying Tang; Lili Gao; Jingwei Mao; Huanyu He; Jia Liu; Xin Cai; Hongli Lin; Taihua Wu
Journal:  Cell Stress Chaperones       Date:  2015-11-17       Impact factor: 3.667

9.  Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance.

Authors:  Norihiro Kikuchi; Yukio Ishii; Yuko Morishima; Yuichi Yageta; Norihiro Haraguchi; Ken Itoh; Masayuki Yamamoto; Nobuyuki Hizawa
Journal:  Respir Res       Date:  2010-03-18

10.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.